Vice President Strategic Development

Mr. Mueller, MSc BBA, has worked in the field of clinical development of oncology drugs for more than a decade and joined Immutep in 2016. After completing his Master of Science in Biotechnology at the Technical University Berlin, he joined Medical Enzymes AG where he focused on therapeutic enzymes for the treatment of cancer. He was responsible for all deliverables of clinical phase I and II studies, built up a clinical team and took over the responsibilities for the strategic clinical development of the lead compound. Since 2012 he worked with Ganymed Pharmaceuticals AG. in developing ideal monoclonal antibodies in the field of immune oncology. He was responsible for the clinical development program of the lead antibody and the setup and management of the clinical team. He successfully completed a multinational randomized phase IIb study with 200+ patients investigating the lead antibody in combination with chemotherapy in patients with advanced metastatic gastric cancer. The study was the core asset of a 1.2 billion USD trade sale deal with Astellas. His efforts in the field of clinical development have led to several publications and patents.